Breakdown | ||||
Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
---|---|---|---|---|
Income Statement | Total Revenue | |||
3.31M | 9.00M | 1.24M | 466.79K | 213.19K | Gross Profit |
-7.11M | 5.32M | -1.92M | -18.41M | -12.55M | EBIT |
-14.58M | -29.95M | -39.48M | -28.89M | -22.53M | EBITDA |
-11.79M | -19.79M | -36.32M | -27.63M | -22.03M | Net Income Common Stockholders |
-14.05M | -29.92M | -41.87M | -28.53M | -20.33M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
15.11M | 11.78M | 42.35M | 21.35M | 43.90M | Total Assets |
17.13M | 34.42M | 68.14M | 45.61M | 46.36M | Total Debt |
0.00 | 7.62M | 11.87M | 12.26M | 484.38K | Net Debt |
-15.11M | -4.17M | -30.48M | -9.10M | -43.42M | Total Liabilities |
3.07M | 14.82M | 24.15M | 18.27M | 2.27M | Stockholders Equity |
14.05M | 19.60M | 43.99M | 27.34M | 44.09M |
Cash Flow | Free Cash Flow | |||
-16.44M | -31.92M | -30.41M | -29.29M | -18.66M | Operating Cash Flow |
-16.44M | -26.97M | -27.28M | -18.86M | -18.28M | Investing Cash Flow |
18.66M | -4.95M | -3.13M | -10.43M | -374.98K | Financing Cash Flow |
1.11M | 202.13K | 52.56M | 6.74M | 816.48K |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
52 Neutral | $5.28B | 3.75 | -42.72% | 2.86% | 17.70% | 2.03% | |
45 Neutral | $13.28M | 0.93 | -92.60% | ― | -70.05% | ― | |
44 Neutral | $14.98M | ― | -135.80% | ― | ― | 52.82% | |
44 Neutral | $13.47M | ― | -65.81% | ― | -3.23% | 38.05% | |
43 Neutral | $16.73M | ― | -97.42% | ― | 234.31% | 79.88% | |
36 Underperform | $10.47M | ― | -123.28% | ― | 650.00% | 89.72% | |
28 Underperform | $19.91M | ― | -541.17% | ― | ― | 99.43% |
On February 12, 2024, Marker Therapeutics’ Board of Directors approved a discretionary award of 30,000 stock options to each of three non-employee directors. These stock options vest annually over three years, aligning with the company’s strategic compensation plan to incentivize leadership and potentially enhance company performance.